Neurocrine Biosciences (NBIX) Operating Expenses (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Operating Expenses for 17 consecutive years, with $807.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 49.01% year-over-year to $807.5 million; the trailing twelve-month figure through Jun 2026 stood at $2.6 billion (up 28.0% YoY), and the FY2025 full-year result was $2.2 billion, up 25.58% from the prior year.
• Operating Expenses grew to $807.5 million in Q2 2026 per NBIX's latest filing, from $621.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $807.5 million in Q2 2026 and bottomed at $300.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $462.8 million across 5 years, with a median of $441.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 73.85% in 2023, then retreated 22.18% in 2024.
• Over 5 years, Operating Expenses stood at $308.6 million in 2022, then gained by 18.24% to $364.9 million in 2023, then soared by 33.1% to $485.7 million in 2024, then increased by 22.42% to $594.6 million in 2025, then surged by 35.81% to $807.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $807.5 million, $621.1 million, and $594.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.